243 related articles for article (PubMed ID: 19324843)
1. Growth factors outside the PDGF family drive experimental PVR.
Lei H; Velez G; Hovland P; Hirose T; Gilbertson D; Kazlauskas A
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3394-403. PubMed ID: 19324843
[TBL] [Abstract][Full Text] [Related]
2. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.
Lei H; Hovland P; Velez G; Haran A; Gilbertson D; Hirose T; Kazlauskas A
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2335-42. PubMed ID: 17460299
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy.
Lei H; Rheaume MA; Kazlauskas A
Exp Eye Res; 2010 Mar; 90(3):376-81. PubMed ID: 19931527
[TBL] [Abstract][Full Text] [Related]
4. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy.
Lei H; Velez G; Hovland P; Hirose T; Kazlauskas A
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):42-8. PubMed ID: 18172073
[TBL] [Abstract][Full Text] [Related]
5. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?
Pennock S; Haddock LJ; Eliott D; Mukai S; Kazlauskas A
Prog Retin Eye Res; 2014 May; 40():16-34. PubMed ID: 24412519
[TBL] [Abstract][Full Text] [Related]
6. PDGF receptors are activated in human epiretinal membranes.
Cui J; Lei H; Samad A; Basavanthappa S; Maberley D; Matsubara J; Kazlauskas A
Exp Eye Res; 2009 Mar; 88(3):438-44. PubMed ID: 19032953
[TBL] [Abstract][Full Text] [Related]
7. Ligand-independent activation of platelet-derived growth factor receptor β promotes vitreous-induced contraction of retinal pigment epithelial cells.
Duan Y; Wu W; Cui J; Matsubara JA; Kazlauskas A; Ma G; Li X; Lei H
BMC Ophthalmol; 2023 Aug; 23(1):344. PubMed ID: 37537538
[TBL] [Abstract][Full Text] [Related]
8. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy.
Pennock S; Rheaume MA; Mukai S; Kazlauskas A
Am J Pathol; 2011 Dec; 179(6):2931-40. PubMed ID: 22035642
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor.
Ikuno Y; Leong FL; Kazlauskas A
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3107-16. PubMed ID: 10967071
[TBL] [Abstract][Full Text] [Related]
10. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor α.
Lei H; Kazlauskas A
Mol Cell Biol; 2014 Jan; 34(1):110-22. PubMed ID: 24190966
[TBL] [Abstract][Full Text] [Related]
11. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells.
Lei H; Kazlauskas A
J Biol Chem; 2009 Mar; 284(10):6329-36. PubMed ID: 19126548
[TBL] [Abstract][Full Text] [Related]
12. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.
Andrews A; Balciunaite E; Leong FL; Tallquist M; Soriano P; Refojo M; Kazlauskas A
Invest Ophthalmol Vis Sci; 1999 Oct; 40(11):2683-9. PubMed ID: 10509666
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.
Pennock S; Haddock LJ; Mukai S; Kazlauskas A
Am J Pathol; 2014 Nov; 184(11):3052-68. PubMed ID: 25261788
[TBL] [Abstract][Full Text] [Related]
14. Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells.
Lei H; Rhéaume MA; Velez G; Mukai S; Kazlauskas A
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):5016-21. PubMed ID: 21642621
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.
Pennock S; Kim D; Mukai S; Kuhnle M; Chun DW; Matsubara J; Cui J; Ma P; Maberley D; Samad A; Van Geest RJ; Oberstein SL; Schlingemann RO; Kazlauskas A
Am J Pathol; 2013 May; 182(5):1659-70. PubMed ID: 23582767
[TBL] [Abstract][Full Text] [Related]
16. TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor.
Ikuno Y; Kazlauskas A
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):41-6. PubMed ID: 11773010
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses.
Pennock S; Kazlauskas A
Mol Cell Biol; 2012 May; 32(10):1955-66. PubMed ID: 22431518
[TBL] [Abstract][Full Text] [Related]
18. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor.
Ikuno Y; Kazlauskas A
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2406-11. PubMed ID: 12091444
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases.
Robbins SG; Mixon RN; Wilson DJ; Hart CE; Robertson JE; Westra I; Planck SR; Rosenbaum JT
Invest Ophthalmol Vis Sci; 1994 Sep; 35(10):3649-63. PubMed ID: 8088954
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy.
Zheng Y; Ikuno Y; Ohj M; Kusaka S; Jiang R; Cekiç O; Sawa M; Tano Y
Jpn J Ophthalmol; 2003; 47(2):158-65. PubMed ID: 12738549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
